Aster Dm Healthcare Ltd. announces an acquisition

The 353.55 million shares were issued to Quality Care India Limited (QCIL) shareholders, not to the existing Aster promoter block. The exchange ratio was 977 Aster shares for every 1,000 QCIL shares held. The disclosure identifies BCP Asia II Topco IV Pte. Ltd. as the principal promoter-side allottee, with the balance issued to other QCIL shareholders. ^[1]

Notes: †Approximate calculation from the latest aggregate promoter holding of 53.72% less the Aster promoter block of 24.01%, applied to the post-allotment equity base of 871.67 million shares. The cited disclosure does not reproduce an exact name-by-name allottee register or the precise share count for each non-BCP allottee. The post-allotment equity base increased from 518.12 million to 871.67 million shares. ^{[1] [2]}

Shareholding effect

• Existing Aster promoters: Their absolute holding remained unchanged at 209,283,923 shares, but their percentage fell from 40.39% to 24.01% because of the enlarged equity base. ^[1]
• BCP and aggregate promoter group: The latest July 2026 post-allotment shareholding pattern reports aggregate promoter ownership of 53.72%, which incorporates the BCP holding. ^[2]
• Public shareholders: Public ownership stood at 46.28%, comprising mutual funds at 15.93%, FII/FPI at 10.31%, retail and other shareholders at 19.49%, and other domestic institutions at 0.55%. ^[2]

Thus, the apparent dilution from 40.39% to 24.01% refers to the original Aster promoter block. On the latest consolidated shareholding classification, the promoter group remains at 53.72% versus 46.28% public, because BCP’s approximately 29.71% stake is included within the promoter category.

The 353.55 million shares should be treated as scheme consideration shares, not as an additional operating cost or a second equity issuance already embedded in the pro-forma numbers. They increase the post-scheme EPS denominator only once. If the pro-forma EPS already assumes the merger as completed for the full reporting period, adding these shares again would double count dilution.

Share-count reconciliation

• 353.55 million shares = 35.355 crore shares.
• The latest annual data available here reports diluted weighted-average shares of 51.61 crore for FY26 and 49.86 crore for FY25.^[3]
• On a mechanical full-period basis, using the FY26 diluted weighted-average count as the pre-issue base:

Updated share count = 51.61 crore + 35.355 crore = 86.965 crore shares

or 869.65 million shares. This is a derived calculation using the 353.55 million shares stated in the question and the reported FY26 denominator.^[3]

• If the Scheme’s pro-forma statements instead use the FY25/pre-scheme base of 49.86 crore shares, the corresponding denominator would be:

49.86 crore + 35.355 crore = 85.215 crore shares

or 852.15 million shares. This is also derived from the reported FY25 denominator.^[3]

EPS treatment

The correct denominator depends on the pro-forma convention:

• Full-period pro-forma basis: use the pre-scheme shares plus 35.355 crore shares for the entire period. The denominator is therefore approximately 86.97 crore shares if the FY26 base is intended.
• Actual-period EPS basis: time-weight the new shares from the scheme’s effective or allotment date:

`Weighted-average shares = old shares × pre-issue fraction + (old shares + 35.355 crore) × post-issue fraction`

Therefore, the 353.55 million shares do not automatically mean that the reported historical weighted-average count should rise by the full amount. They produce a full-period denominator only in the pro-forma presentation; statutory EPS for the year of issuance should reflect the period for which the shares were outstanding.

The key reconciliation check is whether the Scheme documents’ pro-forma balance sheet and EPS denominator already include the 35.355 crore shares. If they do, the updated weighted-average count is the pro-forma denominator—approximately 86.97 crore on the FY26 full-period assumption—and no further addition should be made.

Aster’s post-scheme paid-up equity is approximately 68.24% larger than the pre-scheme baseline, but the latest quarter does not provide enough balance-sheet and operating-profit detail to calculate post-scheme ROE or ROCE reliably. The immediate mechanical effect is dilution of ROE if earnings do not scale with the enlarged equity base; ROCE is less directly affected by the share issuance and depends on the EBIT generated by the assets transferred into the merged entity.

Capital structure bridge

The transaction was described as a cash-neutral merger involving primary share issuance rather than a cash-funded acquisition ^[6]. Therefore, the visible structural change is primarily the enlarged equity base and the addition of Quality Care’s assets, liabilities and earnings—not simply an increase in debt.

ROE and ROCE impact

The last available pre-scheme consolidated KPI snapshot showed:

• Quarterly ROE: 6.00% in Q4 FY26 ^[9]
• Quarterly ROCE: 5.00% in Q4 FY26 ^[10]
• TTM ROE: 16.60% in Q4 FY26 ^[11]
• TTM ROCE: 18.00% in Q4 FY26 ^[12]

The latest Q1 FY27 summary reports a consolidated loss after tax of Rs 4.41 Crores, while the standalone result reported a net loss of Rs 14.30 Crores, including Rs 109.79 Crores of merger-related exceptional costs ^[13]. This points to a weaker reported post-scheme ROE outcome in the transition quarter, but a numerical ROE cannot be derived without average consolidated equity.

A simple share-capital-only sensitivity illustrates the dilution risk: if earnings and all other equity components were unchanged, the 68.24% increase in paid-up capital would reduce the ratio to approximately 59.44% of its pre-scheme level, equivalent to a 40.56% reduction. This is not the reported ROE, because ROE uses average total equity rather than paid-up share capital alone.

ROCE cannot be calculated from the latest quarterly summary because EBIT and capital employed are not provided. Its eventual movement will depend on whether the operating assets acquired through the scheme generate sufficient incremental EBIT. Accordingly, the key post-restructuring test is not the share issuance itself, but whether Quality Care’s earnings contribution grows broadly in line with the enlarged capital employed.